ArticleVaccine2026
XBB 1.5 monovalent booster vaccination stimulates oral mucosal and systemic immune responses in healthy adults.
Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-SARS-CoV-2 nucleoprotein IgA is associated with worse disease severity in critically ill COVID-19 pneumonia patients.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe FDA approved the first monovalent XBB1.5 booster vaccine in September 2023. However, whether this vaccine stimulates mucosal immune responses in the oropharynx, especially neutralizing antibodies, remains understudied.
methodsWe analyzed serum and saliva samples from 28 participants, collected one week before and two to three weeks after the XBB1.5 mRNA vaccination, for neutralizing and binding antibodies to Wuhan and XBB1.5 Spike (S) protein.
resultsWe observed a 2.9-fold increase in Wuhan and a 5.0-fold rise in XBB1.5 serum neutralization titers after mRNA vaccination, which correlated with increased binding antibody levels against the S protein variants in serum. We also examined saliva to assess oral mucosal immune responses to vaccination. Vaccination caused a 1.7-fold increase in ACE2 neutralization in saliva against XBB1.5 (p < 0.0001) and a 1.4-fold increase against Wuhan (p = 0.03). This rise in neutralizing antibody levels in saliva was not associated with the number and timing of previous COVID-19 infections, vaccination status, vaccine type, age, sex, or increases in S-specific IgG in either saliva or serum. Individuals with the largest increase in XBB1.5 neutralization in saliva tended to show a greater rise in S-specific sIgA levels. Depletion of salivary IgA1 or IgG after vaccination revealed that IgA1 was mainly responsible for the increase in ACE2 blocking activity (average reduction in blocking activity with IgA1 depletion = 68%, range 58-81%) compared to IgG (average reduction = 27%, range 0-71%).
conclusionsThe XBB1.5 monovalent vaccine boosts neutralizing antibody levels in blood and mucous membranes, with the largest increase observed against the XBB1.5 variant. This likely reflects the enhancement of cross-reactive antibodies influenced by prior exposure and hybrid immunity, rather than the production of entirely XBB1.5-specific responses. Improved oral mucosal immune responses may reduce the risk of COVID-19 infection and severe illness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.